Skip to main navigation Skip to search Skip to main content

Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial

Marc Cohen, Glenn N. Levine, Karen S. Pieper, Lan Lan, Elliott M. Antman, Philip E. Aylward, Harvey D. White, Neal Kleiman, Robert M. Califf, Kenneth W. Mahaffey

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science